Representation
CF Europe supports joint statement on the new WHO Air Quality Guidelines
CF Europe have given their support to a joint statement on the new World Health Organisation (WHO) Air Quality Guidelines. This joint statement urges nations to implement clean air policies […]
CF Europe Vice President Dimitris Kontopidis has been awarded the European Lung Foundation (ELF) Award
We are proud to announce that Dimitris Kontopidis, the Vice President of CF Europe and CF patient, has been awarded the European Lung Foundation (ELF) Award. For many years, Dimitris […]
Letter to the European Commission: Drug resistance – criteria for identifying antimicrobial medicines reserved for treating humans
In the framework of the new EU Veterinary Medicinal Products Regulation, CF Europe endorsed a letter demanding that antibiotics, which are classified by the World Health Organisation (WHO) as active […]
CHMP positive opinion for Triple Combination of CFTR modulators
We are pleased to inform you that the CHMP, the European Committee for Medicinal Products for Human Use, has given a positive opinion for the use of the triple combination […]
ECRD2020 – The conference on rare diseases happened online on 14-15 May 2020
The ECRD is recognised globally as the largest, patient-led rare disease event in which collaborative dialogue, learning and conversation takes place, forming the groundwork to shape future rare disease policies. Due to the Covid-19 pandemic, […]
CF Europe requests that EMA consider a conditional marketing authorisation for the triple combination
In February, we appealed to the EMA to review the latest triple combination modulator therapy, elexacaftor–tezacaftor–ivacaftor, with a sense of urgency. Today, the urgent need for this therapy could not […]
Our letter to EMA to support the evaluation of the triple combination of CFTR modulators
On behalf of the 48 national Associations in Europe, representing people with CF and their families, CF Europe has sent a letter to the Chair and the Rapporteurs at EMA […]